Logo
x

Search

Subscribe Now

Johnson & Johnson

Johnson & Johnson Submits sBLA to the US FDA for Subcutaneous Induction Regimen of Tremfya (Guselkumab) for Ulcerative Colitis

Johnson & Johnson Submits sBLA to the US FDA for Subcutaneous Induction Regimen of Tremfya (Guselkumab) for Ulcerative Colitis

  • November 25, 2024
Johnson & Johnson to Feature Analysis from P-II (DAHLIAS) Study of Nipocalimab for Treating Sjögren’s Disease at ACR Convergence 2024

Johnson & Johnson to Feature Analysis from P-II (DAHLIAS) Study of Nipocalimab for Treating Sjögren’s Disease at ACR Convergence 2...

  • November 15, 2024
Johnson & Johnson’s Rybrevant Plus Lazcluze Receives the CHMP’s Positive Opinion as a 1L Treatment of EGFR-Mutated NSCLC

Johnson & Johnson’s Rybrevant Plus Lazcluze Receives the CHMP’s Positive Opinion as a 1L Treatment of EGFR-Mutated NSCLC

  • November 15, 2024
Johnson & Johnson’s Edurant Receives the EC Approval for Expanded Use as HIV-1 Therapy in Pediatric Individuals

Johnson & Johnson’s Edurant Receives the EC Approval for Expanded Use as HIV-1 Therapy in Pediatric Individuals

  • October 30, 2024
Johnson & Johnson Reports Tremfya Pooled Analysis from GALAXI-2, 3 and QUASAR Trials

Johnson & Johnson Reports Tremfya Pooled Analysis from GALAXI-2, 3 and QUASAR Trials

  • October 11, 2024
Johnson & Johnson Completes the Acquisition of V-Wave

Johnson & Johnson Completes the Acquisition of V-Wave

  • October 11, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.